Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.,Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. ESMO 2018, abstract LBA50.
RA-patiënt met kanker kan veilig worden behandeld met checkpointremmer
mei 2023 | Dermato-oncologie, Immuuntherapie, Longoncologie, RA